Vor Biopharma (NASDAQ:VOR) Shares Climb 4.8% – Here’s What Happened

Shares of Vor Biopharma Inc. (NASDAQ:VOR – Get Free Report) rose 4.8% on Friday. The stock traded as high as $19.15 and last traded at $19.4040. 113,136 shares traded hands during trading, a decline of 89% from the average session volume of 1,019,825 shares. The stock had previously closed at $18.52.

Analyst Ratings Changes

A number of brokerages have recently commented on VOR. Weiss Ratings upgraded Vor Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, September 14th. Wall Street Zen lowered Vor Biopharma from a “hold” rating to a “sell” rating in a research report on Saturday, October 31st. Citigroup upgraded Vor Biopharma to a “strong-buy” rating in a research report on Thursday, October 15th. Stifel Nicolaus set a $40.00 price target on shares of Vor Biopharma in a report on Monday, November 2nd. Finally, Wedbush upped their price target on shares of Vor Biopharma from $18.00 to $27.00 and gave the stock a “neutral” rating in a report on Wednesday, August 12th. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, Vor Biopharma currently has a consensus rating of “Buy” and a consensus price target of $38.29.

View Our Latest Stock Report on Vor Biopharma

Vor Biopharma Trading Up 6.1%

The firm has a fifty day moving average of $19.55 and a two-hundred day moving average of $17.63.

Vor Biopharma (NASDAQ:VOR – Get Free Report) last announced its quarterly earnings data on Friday, October 30th. The company reported ($1.45) earnings per share for the quarter, missing the consensus estimate of ($0.81) by ($0.64). As a group, equities analysts predict that Vor Biopharma Inc. will post -2.74 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Vor Biopharma

Several hedge funds and other institutional investors have recently modified their holdings of the company. RA Capital Management L.P. increased its holdings in Vor Biopharma by 87.5% during the 3rd quarter. RA Capital Management L.P. now owns 4,503,882 shares of the company’s stock valued at $85,934,000 after purchasing an additional 2,101,787 shares during the period. Nantahala Capital Management LLC increased its stake in shares of Vor Biopharma by 10.3% during the third quarter. Nantahala Capital Management LLC now owns 931,644 shares of the company’s stock valued at $17,776,000 after buying an additional 86,644 shares during the period. Goldman Sachs Group Inc. increased its stake in shares of Vor Biopharma by 126.9% during the third quarter. Goldman Sachs Group Inc. now owns 746,214 shares of the company’s stock valued at $14,238,000 after buying an additional 417,322 shares during the period. Nan Fung Trinity HK Ltd. bought a new position in shares of Vor Biopharma during the third quarter valued at approximately $13,767,000. Finally, Marshall Wace LLP lifted its stake in Vor Biopharma by 486.3% in the third quarter. Marshall Wace LLP now owns 560,715 shares of the company’s stock worth $10,698,000 after acquiring an additional 465,072 shares during the period. 97.29% of the stock is owned by institutional investors.

Vor Biopharma Company Profile

(Get Free Report)

Vor Biopharma is a clinical-stage biotechnology company focused on developing cell therapies for blood cancers. The company combines gene editing of blood stem cells with engineered immune-cell therapies, with the goal of enabling targeted treatment while protecting healthy blood-forming cells. Its research has included trem-cel, an investigational gene-edited stem cell therapy designed to remove the CD33 protein from transplanted cells, and VCAR33, an investigational CAR T-cell therapy targeting CD33.

Featured Articles

Receive News & Ratings for Vor Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vor Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.